Chu et al. [5] demonstrated that BCR-ABL+ stem cells persist in the bone marrow of CML patients in prolonged remission on Imatinib treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.